Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Skin experts unite to tackle melasma confusion

NCT ID NCT07296549

Knowledge-focused Sponsor: Venus Research Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study brings together 15 dermatologists to agree on the best ways to diagnose and treat melasma, a skin condition that causes dark patches on the face. Using a survey method called Delphi, experts will share their knowledge anonymously over several rounds. The goal is to create clear, evidence-based guidelines that help doctors worldwide provide more consistent care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could produce clear, expert-backed guidelines to help doctors treat melasma more consistently and effectively worldwide.
What could go wrong
This is a small, early-stage consensus study with only 15 experts, not a clinical trial testing a treatment. The guidelines may not reflect all patient experiences or lead to new therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 15 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Target population:A purposive sample of experienced clinical dermatologists who actively manage melasma. The panel will include clinicians with diverse practice settings and geographic representation relevant to the study scope.Panel size and rationale:Target enrolment: 20-35 experts.Rationale: this size balances breadth of opinion and feasibility for iterative Delphi rounds; it is large enough to capture diverse viewpoints yet small enough to allow meaningful, anonymized feedback and analysis.Minimum required for analysis: 15 panelists

Ages

25 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Board-certified or equivalent dermatologist, * Minimum of 5 years of post-certification clinical experience in the management of MELASMA, * Willingness to participate in all Delphi rounds. Exclusion Criteria: * Inability or unwillingness to complete Delphi rounds. * Lack of clinical experience with MELASMA * Industry representatives without direct clinical practice

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Melasma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Melanosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Melasma Melasma (facial melasma)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Venus Research Center

    Cairo, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.